WO2013115559A1 - Procédé de préparation de nanoparticules d'albumine incorporant un médicament faiblement soluble dans l'eau - Google Patents

Procédé de préparation de nanoparticules d'albumine incorporant un médicament faiblement soluble dans l'eau Download PDF

Info

Publication number
WO2013115559A1
WO2013115559A1 PCT/KR2013/000752 KR2013000752W WO2013115559A1 WO 2013115559 A1 WO2013115559 A1 WO 2013115559A1 KR 2013000752 W KR2013000752 W KR 2013000752W WO 2013115559 A1 WO2013115559 A1 WO 2013115559A1
Authority
WO
WIPO (PCT)
Prior art keywords
albumin
nanoparticles
peptidyl polymer
poorly water
soluble drug
Prior art date
Application number
PCT/KR2013/000752
Other languages
English (en)
Korean (ko)
Inventor
정지훈
김명구
이민상
장연림
Original Assignee
성균관대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성균관대학교 산학협력단 filed Critical 성균관대학교 산학협력단
Publication of WO2013115559A1 publication Critical patent/WO2013115559A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin

Definitions

  • the present invention relates to a method for producing polyethylene glycol and albumin aggregate nanoparticles containing a poorly water-soluble drug therein that can mediate in vivo delivery through solubilization and stabilization in aqueous solution.
  • paclitaxel a plant-derived anticancer agent
  • solubilizers or organic solvents including various surfactants that can cause irritation or toxicity when administered in vivo to increase the solubility of the drug.
  • emulsifiers for example, paclitaxel, a plant-derived anticancer agent, is a highly hydrophobic, poorly water-soluble drug that is made into an injection by solubilizing in a co-solvent of Cremophor EL and ethanol.
  • Cremophore can cause severe hypersensitivity reactions, including allergic reactions, which requires preparation before treatment through administration of steroids, H2-antagonists, and antihistamines, and 3 to 24 hours of administration time to avoid severe acute allergic reactions. This is necessary. Therefore, patient discomfort due to a long infusion time, patient monitoring during the administration time, preparation and injection process requires a lot of additional costs for hospitalization.
  • a method of using a polymer micelle or microsphere as a carrier of a poorly water-soluble anticancer agent and a method of combining an anticancer agent with a hydrophilic polymer have been studied.
  • the amphiphilic copolymer having hydrophilicity and hydrophobic blocks in one chain is mainly used to form colloidal particles having a core-shell structure which is thermodynamically stable in aqueous solution.
  • Techniques have been developed to encapsulate and deliver poorly water-soluble drugs in a hydrophobic core inside micelles or autoaggregates.
  • albumin has a well-established separation technology and accounts for about 70% of plasma proteins in the blood, which is more economical than other proteins in terms of isolation and use, is easy to acquire, and is highly biocompatible. It is a carrier that is readily available in vivo and can provide a variety of dosage forms, including injections.
  • a method for preparing albumin microspheres by chemical crosslinking using glutaraldehyde as an emulsifying and crosslinking agent US Pat. No. 4,671,954
  • a heat-modifying method for producing microspheres by heating an emulsion mixture at 100 ° C to 150 ° C (Leucuta et al. , International Journal of Pharmaceutics 41: 213-217 (1988)).
  • microspheres are suitable for inclusion of water-soluble materials due to technical limitations in forming water-modified or cross-linked particles in the aqueous phase of water-in-oil emulsions, but not suitable as a carrier for poorly water-soluble materials.
  • a copolymer of polylactide and the like is dissolved in a poorly water-soluble drug and an organic phase and introduced into an aqueous phase to emulsify with a water-in-oil emulsion, whereby nanoparticles are prepared, and a preparation method using albumin as a surfactant for surface stabilization is presented in the literature. (Bazile et al., Biomaterials, 13: 1093 (1992)).
  • Vivorex (VivoRX, USA) developed nanoparticle capsol ® containing a poorly water-soluble drug without the use of cremophors or surfactants using high pressure, high shear forces under certain oil / water emulsion conditions (US patent). 5,439,686, Korean Patent 10-0923172).
  • the present inventors have high solubility in organic solvents without using a surfactant or using chemical bonding method and high pressure and high shear force in an emulsion phase when using a combination of a non-peptidyl polymer and albumin. It was confirmed that coalescing could be formed.
  • the organic solvent is removed, and then, a hydrophilic solvent is added, and the nanoparticles containing poorly water-soluble drugs by self-assembly by simple nanoparticle manufacturing methods such as solvent diffusion and film formation. It was confirmed that the particles can be formed, the nanoparticles containing the poorly water-soluble drug prepared by the above method compared with the albumin nanoparticles containing the known anticancer agent, the anticancer agent is well delivered to confirm that the anticancer effect is excellent The present invention has been completed.
  • the present invention solves the problem of using a surfactant or a high pressure, high shear force in the chemical bonding method and emulsion as a method for producing nanoparticles for in vivo delivery of conventional poorly water-soluble drugs or inorganic nanoparticles for bioimaging. It is to.
  • the present invention provides a method for preparing a non-peptidyl polymer and albumin aggregate and dissolving it in an organic solvent in a fixed molar ratio with a poorly water-soluble drug to remove the organic solvent and to form nanoparticles by self-assembly in a hydrophilic solvent. It is to.
  • non-peptidyl polymer and albumin aggregate nanoparticles prepared by the present invention can mediate in vivo delivery through solubilization and stabilization in aqueous solution, they can be used as carriers of poorly water-soluble drugs or inorganic nanoparticles for bioimaging.
  • the present invention is to provide an association nanoparticle of the non-peptidyl polymer and albumin prepared by the above production method.
  • the present invention is a first step of forming an association of the non-peptidyl polymer and albumin by mixing the non-peptidyl polymer with albumin;
  • the present invention provides a method for producing a conjugated nanoparticles of albumin and a non-peptidyl polymer containing a poorly water-soluble drug or inorganic nanoparticles for bioimaging.
  • Step 1 is a step of mixing the non-peptidyl polymer with albumin to form a combination of the non-peptidyl polymer and albumin, the non-peptidyl polymer can react with the amine group of the albumin to mix the non-peptidyl polymer with albumin It may be substituted with a substituent.
  • the reactor capable of reacting with the amine of albumin is composed of N-hydroxysuccinimide, succinimidyl succinate, succinimide propionate, succinimidyl butanoate, benzotriazole carbonate, aldehyde and catechol It may be selected from the group, but is not limited thereto.
  • the non-peptidyl polymer is polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylene, polyoxazoline, polyurethane, polyphosphazene, polysaccharide, dextran, polyvinyl alcohol, poly Vinyl pyrrolidone, polyvinyl ethyl ether, polyacryl amide, polyacrylate, polycyanoacrylate, lipid polymers, chitin, hyaluronic acid, heparin and combinations thereof.
  • polyethylene glycol it is preferable to use polyethylene glycol, and derivatives of such polyethylene glycol can be used.
  • the derivatives of polyethylene glycol are straight or branched and the branched may have two or more multiple groups.
  • Albumin used in the present invention is preferably human albumin (human albumin, HSA). However, the present invention is not limited thereto.
  • the mole ratio of the non-peptidyl polymer and albumin is preferably 5: 1 to 50: 1.
  • the molecular weight of the non-peptidyl polymer is preferably selected from the range of 750 Da to 300,000 Da.
  • the non-peptidyl polymer may react with an amine group located in the hydrophilic domain of the albumin protein to form a covalent bond.
  • non-peptidyl polymers are hydrophilic polymers, they can exhibit very high solubility not only in aqueous solvents but also in various kinds of organic solvents.
  • the non-peptidyl polymer prepared by step 1 and the albumin association are non-peptidyl polymers bound to the hydrophilic domain of albumin protein, so the hydrophilic region of albumin protein is reduced and the hydrophobic region remains. Compared with the case where only the polymer is used, the solubility in the organic solvent can be further increased by forming the association.
  • Step 2 is a step of preparing a mixture by dissolving a poorly water-soluble drug or inorganic nanoparticles for bioimaging, and the association of the non-peptidyl polymer and albumin on an organic solvent.
  • Albumin molecules act as carriers of hydrophobic substances such as cholesterol and lipid molecules in vivo due to amphipathic chains, and may play an important role in binding to hydrophobic drugs administered in the blood. This property is due to the hydrophobic domain formed inside the albumin molecule.
  • non-peptidyl polymer chains of associations of non-peptidyl polymers with albumin may also be exposed in the organic solvent to help stabilize albumin proteins in organic solvents.
  • phase separation does not occur in the state where the poorly water-soluble drug is dissolved in the association of the non-peptidyl polymer and albumin and the organic solvent, and it is possible to form a film in which the association and the drug are uniformly present when the solvent is removed. .
  • the organic solvent used in the present invention is ethanol, methanol, isopropyl alcohol, butanol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), tetrahydrofuran (THF), acetonitrile, dichloromethane, ethyl acetate, hexane, Diethyl ether, benzene, chloroform, acetone and combinations thereof may be used.
  • a water-soluble solvent may be mixed with the organic solvent. However, it is not limited thereto.
  • organic solvent which does not form an emulsion by mixing with an aqueous phase.
  • organic solvent which does not form an emulsion by mixing with an aqueous phase.
  • examples include, but are not limited to, ethyl alcohol, methyl alcohol, isopropyl alcohol, butyl alcohol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), tetrahydrofuran (THF) or acetonitrile.
  • the molar ratio of the poorly water-soluble drug or the inorganic nanoparticles for bioimaging, the association of the non-peptidyl polymer and albumin is 1: 5 to 1:50.
  • the optimal molar ratio can be set differently depending on the water soluble drug used or the application (eg the long-circulation formulation of SPION).
  • Step 2 takes advantage of the fact that the poorly water-soluble drug can be stabilized in a state in which the non-peptidyl polymer and the association of albumin and the organic solvent are dissolved together without introducing an additional hydrophobic group such as hydrophobic alkyl (acyl group) or bile acid.
  • an additional hydrophobic group such as hydrophobic alkyl (acyl group) or bile acid.
  • albumin may not only serve as a skeleton for introducing hydrophilic groups and hydrophobic groups, but may dissolve poorly water-soluble drugs using hydrophobic domains in the non-peptidyl polymer and albumin itself without introducing additional hydrophobic groups.
  • the poorly water-soluble drug may be an anticancer agent, an antibiotic, an antifungal agent, an anti-inflammatory agent, an immunosuppressive agent or a nutrient
  • the inorganic nanoparticles for biological imaging may be a diagnostic agent or a contrast agent.
  • paclitaxel As anticancer agent, paclitaxel, docetaxel or ortataxel can be used as taxane or its derivative (s).
  • an anticancer agent adriamycin, colchicine, cyclophosphamide, actinomycin, bleomycin, duanorubicin, epirubicin, mitomycin, methotrexate, mitoxantrone, fluorouracil, carboplatin, carmustine (BCNU) ), Methyl CCNU, cisplatin, etoposide, interferon, camptothecin and derivatives thereof, penesterin, tofetecan, vinblastine, vincristine, tamoxifen, piposulfan, irinotecan, gemcitabine, herceptin, vinorelbine, Capecitabine, Alumta, Avastin, Velcade, Tarceva, Neurastar, Lapatinib and Sorafenib can be used.
  • the anticancer agent which can be used is more preferably paclitaxel or camptothecin. However, the present invention is not limited thereto.
  • Antibiotics include neomycin, amikacin, aztreonam, chloramphenicol, palmitic acid chloramphenicol, chloramphenicol sodium succinate, ciprofloxacin, clindamycin, metronidazole, gentamicin, lincomycin, tobramycin, vancomycin, polymyxin B, colistin Metate sodium and colistin can be used.
  • the present invention is not limited thereto.
  • Antifungal agents may include griseofulvin, keloconazole, amphotericin B, nystatin or candicidine. However, the present invention is not limited thereto.
  • nonsteroidal anti-inflammatory agents such as indomethacin, naproxen, ibuprofen, ramipenazone, pyroxicam and steroidal anti-inflammatory agents such as cortisone, dexamethasone, fluazacort, hydrocortisone, prednisolone, prednisone, etc. can be used. Can be. However, the present invention is not limited thereto.
  • cyclosporin As immunosuppressive agents, cyclosporin, azathioprine, myzoribin or tacrolimus can be used. However, the present invention is not limited thereto.
  • fat-soluble vitamins such as vitamins A, D, E, and K can be used.
  • the present invention is not limited thereto.
  • Diagnostic or contrast agents include MR magnetic contrast agents such as iron oxide nanoparticles, fluorocarbons, fat-soluble paramagnetic compounds, and the like; Ultrasound contrast agent; Radiographic agents such as iodo-octane, halocarbon, graphene and the like; And other diagnostics that cannot be delivered without physical or physicochemical modifications of substantially water insoluble properties.
  • the diagnostic or contrast agent that can be used is more preferably iron oxide nanoparticles. However, the present invention is not limited thereto.
  • DMSO dimethyl sulfoxide
  • the organic solvent can be dissolved in both the association of polyethylene glycol and albumin and the poorly water-soluble drug or bioimaging inorganic nanoparticles in the organic solvent.
  • Step 3 is a step of preparing nanoparticles by self-assembly by removing the organic solvent and adding a hydrophilic solvent. Removing the organic solvent and obtaining a mixture in which poorly water-soluble drugs or inorganic nanoparticles for biological imaging are uniformly mixed with a non-peptide polymer and an association of albumin, and having hydrophobicity by self-assembly by adding a hydrophilic solvent to the mixture. The portion of the protein is located inside the particle and the hydrophilic part is located toward the aqueous solution, the poorly soluble drugs or inorganic nanoparticles for bioimaging are collected in the hydrophobic portion and formed into particles having a nano size.
  • step 3 results in the interaction between the poorly water-soluble drug and the hydrophobic domains of albumin, thereby placing the poorly water-soluble drug or inorganic nanoparticles for bioimaging, and the hydrophilic and flexible non-peptidyl polymer chain
  • the hydrophilic solvent when added, it is confirmed that the poorly water-soluble drug is located in the hydrophobic portion inside the particle.
  • the solution containing the nanoparticles of step 3 has the advantage that it has a very stable colloidal properties.
  • the hydrophilic solvent is water, distilled water, sterile water, phosphate buffered saline (PBS), methanol, purified water, ethanol, 1-propanol, 2-propanol, 1-pentanol, 2-butoxyethanol, ethylene glycol, Acetone, 2-butanone, 4-methyl-2-propanone and combinations thereof.
  • PBS phosphate buffered saline
  • methanol purified water, ethanol, 1-propanol, 2-propanol, 1-pentanol, 2-butoxyethanol, ethylene glycol, Acetone, 2-butanone, 4-methyl-2-propanone and combinations thereof.
  • PBS phosphate buffered saline
  • the method of preparing nanoparticles by self-assembly by adding a hydrophilic solvent is preferably a solvent diffusion method or a film formation method, but is not limited thereto.
  • the size of the aggregate nanoparticles prepared in the present invention is preferably 200nm to 500nm. In the case of 200 nm or less, the amount of poorly soluble drugs or inorganic nanoparticles for bioimaging is collected, and in the case of 500 nm or more, the size of the nanoparticles is large, so that the biotransmission ability is poor.
  • association nanoparticles of the non-peptidyl polymer and albumin prepared by the preparation method of the present invention are used as a carrier and thus can safely deliver the drug in vivo.
  • the present invention provides a non-peptidyl polymer and albumin aggregate nanoparticles, characterized in that it comprises a poorly water-soluble drug or inorganic nanoparticles for biological imaging prepared by the method of the present invention.
  • the non-peptide polymer, albumin association and poorly water-soluble drug can be simultaneously dissolved in the organic solvent, the two components are well mixed without additional chemical or physical action. Therefore, the organic solvent is removed and the hydrophilic solvent is removed.
  • To add the nanoparticles can be formed by a solvent diffusion method using a reaction permeable membrane which is a common method for forming nanoparticles or film formation by solvent evaporation.
  • the present invention has a high stability of the nanoparticles prepared compared to the conventional method for producing nanoparticles, the manufacturing step is simple bar non-peptidyl including the anticancer agent prepared by the manufacturing method of the present invention has the effect of reducing the cost and cost
  • the combination of the polymer and albumin has an effect that the anticancer agent is well delivered compared to the albumin nanoparticles known in the art, so that the anticancer effect is excellent.
  • IC 50 35.3 nM
  • anti-cancer activity was measured in the animal model of SK-BR-3 administration, which is a breast cancer cell line of polyethylene glycol and albumin association nanoparticle composition containing paclitaxel prepared by the method according to the present invention, which contains paclitaxel.
  • Albumin nanoparticles were found to show a similar effect to cancer growth (Abraxane ® ) to a superior degree.
  • non-peptidyl polymer and albumin association nanoparticles it is possible to simultaneously dissolve the non-peptidyl polymer, albumin association and poorly water-soluble drug using only one organic solvent. Even if the phosphorus is not applied, the two components are well mixed.
  • the polyethylene glycol and albumin aggregate nanoparticle manufacturing method according to the present invention does not include a surfactant and a solubilizer, and the polyethylene glycol and albumin association having a hydrophobic form while the organic solvent is removed during the preparation of the nanoparticles. Since nanoparticles are formed by self-assembly in which a poorly water-soluble drug is enclosed therein, there is an advantage in that the patient's compliance can be increased without causing hypersensitivity or toxic reactions due to the formulation of poorly water-soluble drugs. In addition, it can be applied to stabilization of inorganic nanoparticles for imaging / diagnosis as well as various poorly water-soluble drugs.
  • association of the non-peptidyl polymer and albumin comprising an anticancer agent prepared by the production method of the present invention has an effect that the anticancer agent is well delivered compared to the albumin nanoparticles known in the prior art has excellent anticancer effect.
  • Figure 1 shows electrophoresis for confirming the formation of polyethylene glycol and albumin association.
  • Figure 2 shows that polyethylene glycol and albumin association dissolve on dimethyl sulfoxide (DMSO).
  • TEM transmission electron microscope
  • TEM transmission electron microscope
  • SEM scanning electron microscope
  • Figure 6 shows the positional characterization of poorly water-soluble drugs in nanoparticles using Nile red.
  • Figure 7 shows the release pattern of paclitaxel from polyethylene glycol and albumin association nanoparticles containing paclitaxel prepared by the film forming method (phosphate buffered saline, PBS with 0.1% sodium salicylate).
  • a polyethylene glycol and albumin association nano-containing hydrophobic fluorescent probes prepared by the film forming method including DiD (red fluorescence, Invitrogen, Carlsbad, CA) and DiI (green fluorescence, Invitrogen, Carlsbad, CA) as model drugs
  • DiD red fluorescence, Invitrogen, Carlsbad, CA
  • DiI green fluorescence, Invitrogen, Carlsbad, CA
  • Figure 9 shows the anticancer activity of breast cancer cell lines (SK-BR-3, MDAMB-453, MCF-7) of polyethylene glycol and albumin aggregate nanoparticles containing paclitaxel prepared by the film forming method.
  • Abraxane ® a commercially available albumin / paclitaxel formulation, was used as a control.
  • FIG. 10 is a graph showing the antitumor and anticancer effects of solid tumor growth in animal tumor models (nude mice nu / nu, SK-BR-3 xenograft) of polyethylene glycol and albumin aggregate nanoparticles containing paclitaxel prepared by the film forming method. Results of observation of prolonged survival. Abraxane ® , a commercially available albumin / paclitaxel formulation, was used as a control.
  • 11 is an animal tumor model of polyethylene glycol and albumin aggregate nanoparticles containing DiD (Invitrogen, Carlsbad, CA), a hydrophobic fluorescent probe prepared by a film forming method, as a model drug (nude mice nu / nu, SK-BR) -3 xenograft) shows the results of the accumulation in solid tumors over time due to the effects of passive tumor targeting.
  • DiD Invitrogen, Carlsbad, CA
  • a hydrophobic fluorescent probe prepared by a film forming method, as a model drug (nude mice nu / nu, SK-BR) -3 xenograft) shows the results of the accumulation in solid tumors over time due to the effects of passive tumor targeting.
  • Fig. 13 shows the stability of polyethyleneglycol and albumin aggregate nanoparticles containing SPION prepared by the film forming method (phosphate saline (PBS, pH 7.4), 0.02% sodium azide as a preservative, 37 ° C).
  • FIG. 14 shows the relaxation (487.5 ⁇ 13.1 mM -1 s -1 ) of polyethylene glycol and albumin aggregate nanoparticles including SPION prepared by the film forming method. It showed better laxity than Feridex ® ( ⁇ 230 mM -1 s -1 ), a commercial iron oxide nanoparticle for MR imaging.
  • Activated polyethyleneglycol (NHS-PEG, Mw 5,000, SunBio, Seoul, Korea) activated with N-hydroxysuccimide (NHS) for human albumin 1:10, 1:20, 1:30, 1
  • the solution was dissolved in PBS at a reaction ratio of: 40, 1:50 (PEG-NHS / albumin) and mixed, followed by stirring for 12 hours.
  • the reaction product was placed in a semipermeable membrane (Spectra / Por, MWCO 10,000), dialyzed in deionized water to remove unreacted PEG, and lyophilized to obtain a uniform white cake.
  • Laemni buffer Laemni sample buffer, 63 mM Tris-HCl, 10% Glycerol, 2% SDS, 0.0025% Bromophenol blue, pH 6.8 to tri-glysine discontinuous acrylamide. Association formation was confirmed by gel electrophoresis (FIG. 1).
  • paclitaxel and 10 mg of albumin-PEG conjugate (1:10 association) were dissolved in dimethylsulfoxide (DMSO) to give a clear solution.
  • DMSO dimethylsulfoxide
  • the mixture was placed in a semipermeable membrane (Spectra / Por, MWCO 10,000) and dialyzed in deionized water to remove the organic solvent through diffusion.
  • the dispersion was filtered through a 0.45 ⁇ m cellulose filter and lyophilized for 48 hours without the addition of the lyophilizer to obtain a uniform white cake, which could be reconstituted into a dispersion by addition of sterile water or PBS.
  • the resulting paclitaxel / albumin-PEG aggregate dispersion was transparent, and transmission electron microscopy (TEM) observation showed that the particles were spherical nanoparticles having a size of 50 to 200 nm (FIGS. 2 and 3).
  • paclitaxel and 10 mg of albumin-PEG conjugate (1:10 association) were dissolved in 50% THF aqueous solution to obtain a clear solution.
  • the mixture was transferred to a rotary evaporator and the solvent was evaporated at reduced pressure at 100 ° C. to form a thin film on the wall of a round-bottom flask.
  • Distilled water was added to the obtained film and dissolved in a magnetic stirrer or an ultrasonic bath to produce a nanoparticle dispersion, which was then filtered through a 0.45 ⁇ m cellulose filter and lyophilized for 48 hours without the addition of a lyophilizer to obtain a uniform white cake. .
  • the obtained cake was reconstituted in a high concentration dispersion by the addition of sterile water or PBS (Fig. 4).
  • camptothecin was dissolved in chloroform / methanol (4: 1), and 10 mg of albumin-PEG (80% methanol) conjugate (1:10 association) was dissolved in 80% aqueous methanol solution. After mixing, a clear mixture solution was obtained. The mixture was transferred to a rotary evaporator and the solvent was evaporated at reduced pressure at 100 ° C. to form a thin film on the wall of a round-bottom flask.
  • Distilled water was added to the obtained film and dissolved in a magnetic stirrer or an ultrasonic bath to produce a nanoparticle dispersion, which was then filtered through a 0.45 ⁇ m cellulose filter and lyophilized for 48 hours without adding a lyophilizer to obtain a uniform white cake. It could be reconstituted into a dispersion by the addition of sterile water or PBS.
  • the obtained Kemptothecin / albumin-PEG aggregate dispersion was transparent, and transmission electron microscope (TEM) observations showed that the particles were spherical nanoparticles having a size of 50 to 200 nm (FIG. 5).
  • Nile red a poorly water-soluble fluorescent substance, causes red-shift of the maximum emission wavelength due to a certain excitation wave depending on the degree of hydrophobicity of the surrounding environment. It can be predicted. Therefore, in order to confirm the location of albumin-PEG aggregate nanoparticles and the properties of their microenvironment, poorly soluble drugs such as paclitaxel and camptothecin are nanoparticles containing nile red, a poorly water-soluble fluorescent substance, using the film forming method described above. Was prepared.
  • the obtained nanoparticles were observed in scanning mode at the emission wavelength at 530 nm (excitation wavelength), and the maximum emission wavelength was shifted from 655 nm to 635 nm. This suggests that the albumin-PEG aggregate nanoparticles carry the poorly water-soluble drug through self-assembly, which is a hydrophobic domain in the protein (FIG. 6).
  • lyophilized nanoparticles were dissolved in DMSO and quantified using HPLC, and when 5% were formulated for target loading, more than 99% of the drugs were nano It was found that the particles were entrapped in the particles.
  • nanoparticles were dialyzed in phosphate-buffered saline (PBS) containing 0.1% sodium salicylate (MWCO 10,000), sampled over time and the amount of paclitaxel released through HPLC analysis. Was quantified (FIG. 7). At this time, 0.1% sodium salicylate was used to increase the solubility of aqueous solution of paclitaxel, a hydrophobic drug.
  • PBS phosphate-buffered saline
  • paclitaxel drug was slowly released from albumin-PEG assembly nanoparticles for a predetermined time.
  • Nanoparticles were prepared by the film forming method as described in Example 3.
  • SK-BR-3 cells which are breast cancer cells, were cultured in a glass-bottomed dish, treated with nanoparticles carrying fluorescent probes, and immobilized with 10% formaldehyde after 6 hours, and observed using a confocal microscope.
  • SK-BR-3, MDA-MB453, and MCF-7 were treated, and cell activity was measured by MTT assay.
  • SK-BR-3 and MCF-7 cell lines showed similar cancer cell growth inhibitory effect to Abraxane (Abraxane ® ), and especially in MDA-MB453 cell line, paclitaxel / albumin-PEG conjugate nanoparticles prepared according to the present invention were control groups. It showed a significantly lower IC 50 value than paclitaxel dissolved in either Abraxane (Abraxane ® ) or DMSO (FIG. 9).
  • SK-BR-3 a breast cancer cell line
  • Animal tumor models were prepared by transdermal injection (100 ⁇ l) into immunodeficient mice (nude mouse, nu / nu).
  • albumin nanoparticles containing the same amount of paclitaxel and the control group were diluted in PBS, and then intravenously injected into the mouse tail according to a prescribed dosing schedule, and the solid cancer volume was measured.
  • the formula for calculating the volume of solid rock is as follows.
  • tumor volume (mm 3 ) [length ⁇ (width) 2 ] / 2
  • Albumin-PEG aggregate nanoparticles containing paclitaxel decreased the volume of solid tumor (tumor) similar to that of Abraxane (Abraxane ® ), and it was observed that it showed an excellent cancer growth inhibitory effect (FIG. 10).
  • the resultant was filtered through a 0.45 ⁇ m cellulose filter and lyophilized for 48 hours without adding a lyophilizer to obtain a uniform brown cake. It could be reconstituted into a dispersion by addition of sterile water or PBS.
  • the obtained SPION / albumin-PEG aggregate dispersion was transparent, and the transmission electron microscope (TEM) observation confirmed that 7 nm SPION particles were enclosed in spherical nanoparticles having a size of about 200 nm (FIG. 12).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)

Abstract

La présente invention concerne un procédé de préparation de nanoparticules d'assemblage de polymère non peptidique et d'albumine incorporant un médicament faiblement soluble dans l'eau et pouvant servir d'intermédiaire à une délivrance in vivo par une solubilisation et une stabilisation dans une solution aqueuse. Plus particulièrement, selon l'invention, un assemblage de polymère non peptidique et d'albumine et un médicament faiblement soluble dans l'eau peuvent être dissous simultanément même si l'on utilise un seul solvant organique et, ainsi, les deux composants sont bien mélangés même sans application d'une action chimique ou physique distincte. De plus, un procédé de préparation de nanoparticules d'assemblage de polyéthylène glycol et d'albumine selon la présente invention ne contient pas de tensioactif ni d'agent solubilisant et ne provoque donc pas de réaction d'hypersensibilité ou de réaction toxique liées à la formule d'un médicament faiblement soluble dans l'eau et peut augmenter la complaisance d'un patient. En outre, la présente invention peut également être utile pour la stabilisation, et analogue, de nanoparticules inorganiques à des fins d'imagerie/diagnostic et de divers médicaments faiblement solubles dans l'eau.
PCT/KR2013/000752 2012-01-30 2013-01-30 Procédé de préparation de nanoparticules d'albumine incorporant un médicament faiblement soluble dans l'eau WO2013115559A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120009253 2012-01-30
KR10-2012-0009253 2012-01-30

Publications (1)

Publication Number Publication Date
WO2013115559A1 true WO2013115559A1 (fr) 2013-08-08

Family

ID=48905532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/000752 WO2013115559A1 (fr) 2012-01-30 2013-01-30 Procédé de préparation de nanoparticules d'albumine incorporant un médicament faiblement soluble dans l'eau

Country Status (2)

Country Link
KR (1) KR101455921B1 (fr)
WO (1) WO2013115559A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109142759A (zh) * 2018-08-31 2019-01-04 江苏力博医药生物技术股份有限公司 一种高质量血型检测卡用微柱凝胶的制备方法
CN113425700A (zh) * 2021-06-28 2021-09-24 中山大学 一种基于蛋白自组装的纳米药物载送系统的构建及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113577075A (zh) * 2021-08-20 2021-11-02 滕兆刚 一种纳米药物及其制备方法、应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20070082838A1 (en) * 2005-08-31 2007-04-12 Abraxis Bioscience, Inc. Compositions and methods for preparation of poorly water soluble drugs with increased stability
KR100851933B1 (ko) * 2005-12-02 2008-08-12 연세대학교 산학협력단 망간 산화물 나노입자를 포함하는 자기공명 영상제
KR100923172B1 (ko) * 1997-06-27 2009-10-22 아브락시스 바이오사이언스, 엘엘씨 신규 약물 제제
US20100297243A1 (en) * 2009-04-15 2010-11-25 Desai Neil P Prion free nanoparticle compositions and methods of making thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080037083A (ko) * 2005-08-18 2008-04-29 글로보아시아 엘엘씨 약학용 등급의 유기 철 화합물, 그 용도 및 이의 제조 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
KR100923172B1 (ko) * 1997-06-27 2009-10-22 아브락시스 바이오사이언스, 엘엘씨 신규 약물 제제
US20070082838A1 (en) * 2005-08-31 2007-04-12 Abraxis Bioscience, Inc. Compositions and methods for preparation of poorly water soluble drugs with increased stability
KR100851933B1 (ko) * 2005-12-02 2008-08-12 연세대학교 산학협력단 망간 산화물 나노입자를 포함하는 자기공명 영상제
US20100297243A1 (en) * 2009-04-15 2010-11-25 Desai Neil P Prion free nanoparticle compositions and methods of making thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109142759A (zh) * 2018-08-31 2019-01-04 江苏力博医药生物技术股份有限公司 一种高质量血型检测卡用微柱凝胶的制备方法
CN109142759B (zh) * 2018-08-31 2021-08-06 江苏力博医药生物技术股份有限公司 一种高质量血型检测卡用微柱凝胶的制备方法
CN113425700A (zh) * 2021-06-28 2021-09-24 中山大学 一种基于蛋白自组装的纳米药物载送系统的构建及应用

Also Published As

Publication number Publication date
KR20130088081A (ko) 2013-08-07
KR101455921B1 (ko) 2014-11-12

Similar Documents

Publication Publication Date Title
Çirpanli et al. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery
WO2011142515A1 (fr) Liposomes asymétriques pour l'encapsulation hautement efficace d'acides nucléiques et composés anioniques hydrophiles, et leur procédé de préparation
WO2018186725A1 (fr) Composition pharmaceutique pour le traitement du cancer
US20130274226A1 (en) Silica nanoparticle agent conjugates
WO2011062420A2 (fr) Nanoparticules de ciblage de tumeurs et leurs procédés de préparation
Wang et al. Tracking translocation of self-discriminating curcumin hybrid nanocrystals following intravenous delivery
KR101064901B1 (ko) 난수용성 항암제와 신규 블록 공중합체를 포함하는 미셀조제물
WO2009102121A2 (fr) Nanoparticules lipidiques solides pour l'administration de médicaments, leur procédé de production, et préparation injectable comprenant lesdites nanoparticules
WO2023287111A1 (fr) Complexe de micelles et vecteur de médicament le comprenant
Li et al. Oral insulin delivery by epithelium microenvironment-adaptive nanoparticles
WO2013115559A1 (fr) Procédé de préparation de nanoparticules d'albumine incorporant un médicament faiblement soluble dans l'eau
Xia et al. Enhanced transport of nanocage stabilized pure nanodrug across intestinal epithelial barrier mimicking Listeria monocytogenes
JP2012526049A (ja) 腫瘍治療のためのｓｎ−３８を含有するポリマーミセル
WO2017200218A1 (fr) Nanocomposite auto-assemblé à base d'interaction supramoléculaire, comprenant de l'albumine, son procédé de production et son utilisation
WO2018230788A1 (fr) Composition pour l'administration d'un médicament par voie orale contenant de l'oxaliplatine et son procédé de préparation
Yusuf et al. Formulation design and cell cytotoxicity of curcumin-loaded liposomal solid gels for anti-Hepatitis C virus
WO2021141319A2 (fr) Nanoparticules d'administration de médicament modifiées en surface avec un peptide de ciblage de cellules cancéreuses du cerveau, leur méthode de préparation et leur utilisation
CN101357939B (zh) 蛋白质偶联物及其药物组合物
WO2014030975A1 (fr) Procédé de production d'un agent anticancéreux à base de nanotubes de carbone supprimant la résistance des cellules cancéreuses
WO2018092984A1 (fr) Nanoporteur pour le marquage fluorescent sélectif des cellules cancéreuses, et procédé de préparation de ce dernier
CN105288631A (zh) 一种新型抗癌药物纳米制剂及其制备方法
US8524783B2 (en) Polymer micelles containing anthracylines for the treatment of cancer
CN106794150B (zh) 高药物负载的聚(2-氰基丙烯酸烷基酯)纳米胶囊
WO2023054849A1 (fr) Composition pharmaceutique pour le traitement de maladies inflammatoires
WO2022196865A1 (fr) Composition de statine lipophile présentant une solubilité et une perméabilité améliorées et ses utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13743317

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13743317

Country of ref document: EP

Kind code of ref document: A1